ADC Therapeutics SA (ADCT)vsEli Lilly and Company (LLY)
ADCT
ADC Therapeutics SA
$1.55
+0.65%
HEALTHCARE · Cap: $195.33M
LLY
Eli Lilly and Company
$1,409.27
-0.11%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 108542% more annual revenue ($86.46B vs $79.58M). LLY leads profitability with a 31.9% profit margin vs -121.8%. LLY earns a higher WallStSmart Score of 74/100 (B).
ADCT
Avoid25
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Areas to Watch
2.2% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -706.0% — below average capital efficiency
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADCT
The strongest argument for ADCT centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : ADCT
The primary concerns for ADCT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
ADCT profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
ADCT carries more volatility with a beta of 1.86 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 25/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADC Therapeutics SA
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?